Ozempic's Global Impact: Revolutionary Weight Loss Results Raise Critical Long-Term Questions

💊 How It Works: A Drug That Mimics Nature

Semaglutide belongs to the class of GLP-1 receptor agonists, a group of drugs that mimic the action of the natural hormone GLP-1 (glucagon-like peptide-1). This hormone is released after eating and plays a central role in regulating blood sugar, the rate of stomach emptying, and the satiety signals that reach the brain.

What makes semaglutide unique is its triple mechanism of action: it slows gastric emptying, creating a feeling of fullness for hours; it reduces appetite by acting on the brain's reward centers; and it improves glycemic control. It was originally developed by Novo Nordisk for the treatment of type 2 diabetes, but the dramatic weight loss observed in patients led to its approval as a weight management drug in 2021 by the FDA.

📊 The Numbers Are Impressive

Three large reviews commissioned by the World Health Organization (WHO) to the Cochrane organization, published in February 2026, confirmed the impressive results. Semaglutide (Ozempic/Wegovy) achieved an average weight loss of about 11% over 24 to 68 weeks, based on data from 18 randomized clinical trials with 27,949 participants. Tirzepatide (Mounjaro/Zepbound) was even more effective, reaching an average weight reduction of 16% after 12 to 18 months.

Beyond weight loss, the SELECT study — a clinical trial with 17,604 patients across 41 countries — showed a 20% reduction in the risk of major cardiovascular events in overweight patients without diabetes. It was the first time a pharmaceutical intervention for obesity was rigorously proven to reduce cardiovascular risk. Participants taking semaglutide lost an average of 9.4% of their body weight over 40 weeks.

⚠️ The Shadows Behind the Impressive Numbers

However, the picture isn't as rosy as the headlines suggest. One of the most significant concerns involves the composition of the weight being lost. Researchers from the University of Cambridge and UCL issued a warning in February 2026: muscle mass may account for up to 40% of the total weight loss during treatment. Muscle loss increases the risk of weakness, falls, injuries, and osteoporosis — especially in elderly patients.

Weight regain after stopping is also a critical problem. A large review of 11 studies with 2,466 participants, published in BMC Medicine in July 2025, showed that significant weight regain begins as early as 8 weeks after stopping. Within 20 weeks, patients had regained an average of 2.5 kg, with those who had lost more weight tending to regain more.

In addition to gastrointestinal side effects — nausea, diarrhea, constipation — more concerning findings have emerged. In the SELECT study, 16.6% of patients taking semaglutide discontinued treatment due to side effects, compared to 8.2% in the control group. Researchers have also reported increased risk of gallstones and a rare form of vision loss ("ocular stroke"), while thyroid tumors were observed in rodent experiments — although this has not been confirmed in humans.

🧬 Beyond Weight Loss: New Horizons

Perhaps the most fascinating aspect of the Ozempic story are the discoveries beyond obesity. Studies suggest that semaglutide may reduce symptoms of alcohol use disorder, possibly by acting on the same brain reward mechanisms that reduce food cravings. Researchers are also examining potential benefits for kidney disease, non-alcoholic fatty liver disease (NAFLD), and even colon cancer.

The great hope was Alzheimer's disease. Unfortunately, two clinical trials lasting two years ended in disappointment: semaglutide failed to significantly slow the progression of the disease. Nevertheless, encouraging evidence suggests a reduced risk of epilepsy in diabetic patients using GLP-1 drugs.

🔮 The Future: New Generations and Open Questions

The pharmaceutical industry is already preparing for the next generation. Novo Nordisk announced three new experimental weight loss drugs, including an oral formula that will eliminate the need for weekly injections. Meanwhile, researchers are developing drugs that target metabolism in different ways, promising permanent fat loss without the downsides of lifelong treatment.

The critical questions remain: what are the true long-term effects beyond the 3-4 years of data we have? How will equitable access be ensured, given that prices remain exorbitant? The semaglutide patent expires in 2026, which is expected to bring cheaper generics to market.

The Cochrane reviews also highlight a credibility issue: the vast majority of studies were funded by the very pharmaceutical companies that manufacture them, with deep involvement in the design, conduct, and publication of results. Independent research from a public health perspective is more necessary than ever.

Semaglutide is undoubtedly transforming medicine. But its story reminds us that no drug is a miracle without asterisks. The real challenge isn't just losing weight — it's staying healthy long-term.